Medicare Enrolled
Dr. Khai Vu, M.D.
Hematology & Oncology · Fountain Valley, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Vu from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Vu?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Vu
Dr. Khai Vu is a hematology & oncology specialist in Fountain Valley, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Vu performed 14,285 Medicare services across 1,336 unique beneficiaries.
Between the years covered by Open Payments, Dr. Vu received a total of $12,579 from 69 pharmaceutical and/or device companies across 403 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Vu is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 26% volume in CA
$12,579 industry payments
Medicare Practice Summary
Medicare Utilization ↗14,285
Medicare services
Top 26% in CA for hematology & oncology
1,336
Unique beneficiaries
$23
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~752 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, heparin sodium, (heparin lock flush), per 10 units | 3,502 | $0 | $0 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
2,340 | $3 | $9 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,034 | $0 | $1 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,266 | $106 | $236 |
| Anti-nausea injection (ondansetron/Zofran) | 1,184 | $0 | $2 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
433 | $12 | $29 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
364 | $70 | $181 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
355 | $152 | $360 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
339 | $30 | $82 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
315 | $12 | $33 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
314 | $2 | $5 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
291 | $26 | $65 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
231 | $120 | $312 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
143 | $1 | $3 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
114 | $59 | $147 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
112 | $58 | $146 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
110 | $1 | $21 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
105 | $66 | $158 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
87 | $1 | $3 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
74 | $41 | $98 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
68 | $14 | $41 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
62 | $25 | $65 |
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
60 | $18 | $28 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
54 | $18 | $44 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
53 | $100 | $235 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
52 | $0 | $3 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
48 | $139 | $313 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
31 | $36 | $114 |
| New patient office visit, complex (60-74 min) | 27 | $186 | $365 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
25 | $8 | $10 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
25 | $150 | $377 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
25 | $18 | $42 |
| Initial hospital admission, low complexity Initial hospital inpatient or observation care for a new patient involving straightforward or low-level medical decision making, with at least 40 minutes total time on the date of the encounter. |
16 | $69 | $209 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
15 | $84 | $236 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
11 | $109 | $265 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
11.6% high complexity
67.3% medium
21.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$12,579
Total received (2018-2024)
Avg $1,797/year across 7 years
Top 29% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
69
Companies
403
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,611 (76.4%)
Other
Charitable contributions, space rental, and other categories
$1,448 (11.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,374 (10.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$146 (1.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,236
2023
$3,258
2022
$2,236
2021
$2,361
2020
$178
2019
$127
2018
$183
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,448
Merck Sharp & Dohme LLC
$325
ABBVIE INC.
$137
Gilead Sciences, Inc.
$116
Genentech USA, Inc.
$113
Eisai Inc.
$110
Daiichi Sankyo Inc.
$109
Adaptive Biotechnologies Corporation
$101
BeiGene USA, Inc.
$97
Takeda Pharmaceuticals U.S.A., Inc.
$93
PUMA BIOTECHNOLOGY, INC.
$92
Janssen Biotech, Inc.
$88
AstraZeneca Pharmaceuticals LP
$88
PFIZER INC.
$85
Tempus AI, Inc
$81
Bayer Healthcare Pharmaceuticals Inc.
$72
Exelixis Inc.
$65
PharmaEssentia USA Corporation
$64
Regeneron Healthcare Solutions, Inc.
$63
Celgene Corporation
$61
E.R. Squibb & Sons, L.L.C.
$59
Karyopharm Therapeutics Inc.
$57
Boehringer Ingelheim Pharmaceuticals, Inc.
$53
ARRAY BIOPHARMA INC
$53
SpringWorks Therapeutics, Inc.
$51
GlaxoSmithKline, LLC.
$51
SOBI, INC
$51
Lilly USA, LLC
$45
Immunocore Limited
$39
EMD Serono, Inc.
$33
Alexion Pharmaceuticals, Inc.
$31
Rigel Pharmaceuticals, Inc.
$31
Blueprint Medicines Corporation
$29
GENZYME CORPORATION
$29
Incyte Corporation
$29
Telix Pharmaceuticals
$28
TAIHO ONCOLOGY, INC.
$28
ADC Therapeutics America, Inc.
$24
Mirati Therapeutics, Inc.
$24
Acrotech Biopharma Inc.
$23
Astellas Pharma US Inc
$23
Deciphera Pharmaceuticals Inc.
$22
SERVIER PHARMACEUTICALS LLC
$17
Top 3 companies account for 45.1% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,768
AstraZeneca Pharmaceuticals LP
$1,533
Merck Sharp & Dohme LLC
$578
Amgen Inc.
$540
Janssen Biotech, Inc.
$519
E.R. Squibb & Sons, L.L.C.
$509
Gilead Sciences, Inc.
$436
Pharmacyclics LLC, An AbbVie Company
$384
Eisai Inc.
$364
PFIZER INC.
$361
Pharmacyclics LLC, an AbbVie Company
$297
GlaxoSmithKline, LLC.
$268
Celgene Corporation
$263
Genentech USA, Inc.
$256
Lilly USA, LLC
$238
Regeneron Healthcare Solutions, Inc.
$215
Takeda Pharmaceuticals U.S.A., Inc.
$208
ABBVIE INC.
$178
Daiichi Sankyo Inc.
$166
BeiGene USA, Inc.
$166
Bayer Healthcare Pharmaceuticals Inc.
$155
GENZYME CORPORATION
$150
AbbVie Inc.
$141
Rigel Pharmaceuticals, Inc.
$139
Blueprint Medicines Corporation
$139
Boehringer Ingelheim Pharmaceuticals, Inc.
$130
Incyte Corporation
$126
Ironwood Pharmaceuticals, Inc
$125
PharmaEssentia USA Corporation
$117
Seagen Inc.
$115
EMD Serono, Inc.
$113
Karyopharm Therapeutics Inc.
$103
Adaptive Biotechnologies Corporation
$101
PUMA BIOTECHNOLOGY, INC.
$92
Myriad Genetic Laboratories, Inc.
$88
Exelixis Inc.
$84
Astellas Pharma US Inc
$82
Deciphera Pharmaceuticals Inc.
$81
Tempus AI, Inc
$81
Stemline Therapeutics Inc.
$80
ImmunoGen, Inc.
$73
EISAI INC.
$71
SERVIER PHARMACEUTICALS LLC
$69
ADC Therapeutics America, Inc.
$65
TAIHO ONCOLOGY, INC.
$54
ARRAY BIOPHARMA INC
$53
SpringWorks Therapeutics, Inc.
$51
SOBI, INC
$51
Alexion Pharmaceuticals, Inc.
$50
Taiho Oncology, Inc.
$47
Acrotech Biopharma Inc.
$43
Teva Pharmaceuticals USA, Inc.
$41
Mirati Therapeutics, Inc.
$40
Bayer HealthCare Pharmaceuticals Inc.
$40
Immunocore Limited
$39
GE HealthCare
$35
Telix Pharmaceuticals
$28
Sobi, Inc
$28
AVEO Pharmaceuticals, Inc.
$26
Foundation Medicine, Inc.
$24
MorphoSys, US Inc.
$22
Puma Biotechnology, Inc.
$22
Ipsen Biopharmaceuticals, Inc
$21
Jazz Pharmaceuticals Inc.
$19
Kyowa Kirin, Inc.
$18
Organon LLC
$15
LeMaitre Vascular, Inc.
$15
Pharmacosmos Therapeutics Inc.
$14
Advanced Accelerator Applications
$14
Top 3 companies account for 30.8% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · ANASTOCLIP · AYVAKIT · Alecensa · Asparlas · BAVENCIO · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BOTOX · BRAFTOVI · BRUKINSA · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CYRAMZA · Columvi · DARZALEX · DOPTELET · ELAHERE · ELIQUIS · ELITEK · ELZONRIS · ENHERTU · EPKINLY · ERLEADA · EXKIVITY · Elahere · Enhertu · FOTIVDA · FRUZAQLA · Fabhalta · GAZYVA · GILOTRIF · Halaven · IBRANCE · ICLUSIG · ILLUCCIX · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · Lenvima · Linzess · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONTRUZANT · OPDIVO · OPDUALAG · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROMACTA · Padcev · Polivy · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · RETEVMO · RYZNEUTA · Rezlidhia · SARCLISA · SCEMBLIX · Somatuline Depot · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TIBSOVO · Tavalisse · Tecentriq · Trodelvy · Truxima · UBRELVY · ULTOMIRIS · VENCLEXTA · VERZENIO · VYXEOS · XPOVIO · XTANDI · Xofigo · Xospata · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (76%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
208
Per 100K population
6.6
County median income
$113,702
Nearest hospital
UCI HEALTH - FOUNTAIN VALLEY
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Vu is a mixed practice specialist, with above-average Medicare volume (top 26% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Vu experienced with injection, heparin sodium, (heparin lock flush), per 10 units?
Based on Medicare claims data, Dr. Vu performed 3,502 injection, heparin sodium, (heparin lock flush), per 10 units services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Vu receive payments from pharmaceutical companies?
Yes. Dr. Vu received a total of $12,579 from 69 companies across 403 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Vu's costs compare to other hematology & oncology specialists in Fountain Valley?
Dr. Vu's average Medicare payment per service is $23. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Vu) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Fountain Valley
Browse hematology & oncology specialists in Fountain Valley ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology